Lung Cancer Therapeutic Market to Witness 9% CAGR (2021-2027) Due to Growing Development of Pharmaceutical Companies | Market insights from UnivDatos

NOIDA, IndiaπŸ‡§πŸ‡· November 24, 2022 /PRNewswire/ — According to a new report published by UnivDatos Markets Insights, the Market for lung cancer therapies expected to reach $48 billion in 2027, growing at a CAGR of 9% from 2021-2027. The analysis was segmented into disease type (non-small cell lung cancer, small cell lung cancer); treatment (chemotherapy, radiotherapy, immunotherapy, targeted therapy, others); type of molecule (small molecules, biological); distribution channel (hospital pharmacies, e-commerce, retail pharmacies, others); Region/Country.

Logo UnivDatos Market Insights

Click here to view report description and TOC

https://univdatos.com/report/lung-cancer-therapeutics-market/

The Lung Cancer Therapeutics Market report has been aggregated by collecting informative data on various dynamics such as market drivers, restraints, and opportunities. This groundbreaking report makes use of various analyzes to get a closer look at the Lung Cancer Therapeutics market. The Lung Cancer Therapeutics market report offers an in-depth analysis of the latest industry developments and trending factors that are influencing the growth of the market. Additionally, this market research statistical repository examines and estimates the Lung Cancer Therapeutics market at the global and regional levels.

Request for sample pages

https://univdatos.com/get-a-free-sample-form-php/?product_id=28308

Market overview

Experts forecast the Lung Cancer Treatment market to grow at a CAGR of around 9% during 2021-2027.πŸ‡§πŸ‡· Lung cancer is the second most common cancer and the leading cause of cancer death in men and women in the United StatesπŸ‡§πŸ‡· The increasing prevalence of lung cancer due to lifestyle change with high smoking habits that lead to huge population of lung carcinoma is one of the main factors that results in an increase in the number of people with lung cancer. For example, according to the American Lung Association, smoking, the leading cause of non-small and small cell lung cancer, contributes to 80% and 90% of lung cancer deaths in women and men, respectively. Men who smoke are 23 times more likely to develop lung cancer. Women are 13 times more likely to never smoke. The growing geriatric population with NSCLC, along with increased adoption and wide availability of advanced lung cancer therapeutics in the region, is expected to drive the market for lung cancer therapies. In addition, several factors, such as smoking, unhealthy diet, sedentary lifestyle and advanced age, increase the risk and diagnosis of these diseases. Therefore, the lung cancer therapeutic devices market is expected to witness significant growth during the forecast period.πŸ‡§πŸ‡·

Some of the major players operating in the market include AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Merck & Co, Pfizer Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd. , AbbVie, Inc.

Impact of COVID-19

The COVID-19 pandemic has had an adverse impact on the global lung cancer therapies industry. Several countries have imposed national lockdowns as part of measures to limit the spread of the coronavirus. As a result, it caused widespread disruption in cancer treatment. In light of the pandemic, many people with cancer face challenges, including delays in diagnosis and treatment.

The global Lung Cancer Treatment market report is studied thoroughly with various aspects that would help the interested parties to make their decisions more accurately.

  • On the basis of treatment, the market is segmented into chemotherapy, radiotherapy, immunotherapy, targeted therapy and others. Among these, the targeted therapy category accounted for most of the global lung cancer therapy. Targeted therapy is a type of cancer treatment that targets specific cancer cells in the body and does not affect the functioning of normal healthy cells, which leads to minimal adverse effects. The continued development of new products due to technological advances that would lead to the production of innovative therapies and drugs is expected to strengthen the segment market in the forecast period.

  • Based on the type of molecule, the market is categorized into small molecules and biologics. Among these, small molecules are expected to witness faster growth during the forecast period. This is mainly due to the fact that it is increasingly used in the treatment of lung cancer, due to the growing preference of professionals for nanotherapy. Also, small molecule drugs are small enough to easily enter cells, so they are used to target inside cells.

Have a look at the chapters- https://univdatos.com/report/lung-cancer-therapeutics-market/

The geographic segmentation of the Lung Cancer Therapeutics market includes:

  • North America πŸ‡§πŸ‡·United StatesπŸ‡§πŸ‡· Canadaand rest of North AmericaπŸ‡§πŸ‡·

  • Europe πŸ‡§πŸ‡·GermanyπŸ‡§πŸ‡· UKπŸ‡§πŸ‡· SpainπŸ‡§πŸ‡· ItalyπŸ‡§πŸ‡· Franceand the rest EuropeπŸ‡§πŸ‡·

  • Asia Pacific πŸ‡§πŸ‡·ChinaπŸ‡§πŸ‡· JapanπŸ‡§πŸ‡· IndiaπŸ‡§πŸ‡· Australiaand the rest Asia PacificπŸ‡§πŸ‡·

  • Rest of the world

North America represented an important part of the market for lung cancer therapies. The main contributors to the growth of this market are the United States and CanadaπŸ‡§πŸ‡· This is mainly due to the increase in the incidence of cancer that causes death in countries such as the United States and CanadaπŸ‡§πŸ‡· Growing lung cancer is more common in men than women, particularly African-American men. The chance of getting lung cancer increases with age, and of course, a history of smoking has contributed significantly to the state’s considerable growth in the US market for lung cancer therapies.

Major players targeting the market include

competitive scenario

The degree of competition between prominent global companies has been worked out by analyzing several of the major players operating around the world. The expert team of research analysts sheds light on various characteristics such as global market competition, market share, latest industry advancements, innovative product launches, partnerships, mergers or acquisitions by leading companies in the industry. Lung Cancer Therapeutic Market. Major players have been analyzed using research methodologies to gain insight views on global competition.

Key issues resolved through this market research analytical report include:

  • What are the latest trends, new standards and technological advances in the Lung Cancer Therapeutics market?

  • What factors influence the Lung Cancer Therapeutics market in the forecast period?

  • What are the global challenges, threats and risks of the Lung Cancer Therapeutics market?

  • What factors are driving and constraining the global Lung Cancer Therapeutics market?

  • What are the most demanding global regions of the Lung Cancer Therapeutics market?

  • What will be the size of the global market in the coming years?

  • What are the crucial market acquisition strategies and policies applied by global companies?

We understand the requirement of different companies, regions and countries, we offer customized reports according to your business nature and geography needs. Please let us know if you have any custom needs.

About UnivDatos Market Insights (UMI)

Browse other related research reports from UnivDatos Market Insights

Market for lung cancer therapies report coverage

report attributeand

Details

base year

2020

forecast period

2021-2027

growth momentum

Accelerate with a CAGR of 9%

2027 market size

$48 billion

Regional analysis

North America, Europe, APAC, Rest of World

Main contributing region

NoNorth America dominate the Global lung cancer therapy market

Main countries covered

United States, Canada, Germany, United Kingdom, Italy, France, Spain, China, Japan, India, TheAustralia

Profiled companies

AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Merck & Co, Pfizer Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., AbbVie, Inc.

Report Scope

Market trends, drivers and constraints; Revenue Estimation and Forecast; Segmentation Analysis; Impact of COVID-19; Demand and Supply Side Analysis; Γ‡competitive landscapeπŸ‡§πŸ‡· company profile

Covered Segments

By Type of Disease; By treatment, by type of molecule; By Distribution ChannelπŸ‡§πŸ‡· by region/country

About UnivDatos Market Insights (UMI)

UnivDatos Market Insights (UMI) is a passionate market research company and a subsidiary of Universal Data Solutions. We believe in delivering insights through market intelligence reports, custom business research and primary research. Our research studies span topics across the globe, we cover markets in over 100 countries using smart research techniques and agile methodologies. We offer in-depth studies, in-depth analysis and custom reports that help shape winning business strategies for our clients.

Contact

Market insights from UnivDatos
Ankita Gupta
Director of Operations
Phone: +91-7838604911
Email: [email protected]
Website: https://univdatos.com/

Logo: https://mma.prnewswire.com/media/1225049/UnivDatos_Logo.jpg

spin-off

spin-off

See original content: https://www.prnewswire.com/news-releases/lung-cancer-therapeutics-market-to-witness-cagr-of-9-2021-2027-due-to-the-increasing-development – por-pharmaceutical-companies-univdatos-market-insights-301686704.html

SOURCE UnivDatos Market Insights Pvt. Ltd.

Lung Cancer Therapeutic Market to Witness 9% CAGR (2021-2027) Due to Growing Development of Pharmaceutical Companies | Market insights from UnivDatos

Leave a Reply

Your email address will not be published.

Scroll to top